Clinical trial
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT)
NCT02508116 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT)
- Lead sponsor
- University of Pennsylvania
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- November 30, 2014
- Completion date
- August 31, 2017
- Enrollment
- 509 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.